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Abstract Lymphoma-associated hemophagocytic syndrome
(LAHS) is a serious disorder, and its early diagnosis and
treatment with appropriate chemotherapy are very important.
However, reliable markers for early diagnosis of LAHS have
not been identified. We screened serum cytokines using a
newly introduced assay system, cytometric bead array
(CBA), and identified interferon-inducible protein 10 (IP-
10)/CXCL10 and monokine induced by interferon gamma
(MIG)/CXCL9 as useful markers. Serum concentrations of
IP-10 and MIG at the time of LAHS diagnosis were greater
than 500 and 5,000 pg/ml, respectively. The sensitivity and
specificity for LAHS diagnosis were 100 and 95 %, respec-
tively, when we set the above values as the cut-off levels.
Serum levels of these two chemokines were already elevated
at the time of admission and significantly decreased after
successful treatment, indicating their usefulness for both
the diagnosis and therapeutic outcomes for LAHS. IP-10
and MIG were also useful in distinguishing severe from
moderate/mild LAHS, and B-cell-type LAHS from T-cell/
natural killer cell-type LAHS. Furthermore, IP-10 and MIG
were of use to distinguish LAHS from sepsis in patients with
hematologic malignancies. Rapid measurement of IP-10 and
MIG byCBA appeared to be important for early diagnosis and
treatment of LAHS.
Keywords Lymphoma-associated hemophagocytic
syndrome . IP-10 .MIG . Cytometric bead array
Introduction
Hemophagocytic syndrome (HPS) is a serious disorder charac-
terized by persistent high-grade fever, hepatosplenomegaly,
pancytopenia, abnormal coagulopathy, and hemophagocytosis
by macrophages in the bone marrow, spleen, liver, and lymph
node [1–3]. The cause of HPS has been supposed to be hyper-
activation of macrophages, Tcells, and natural killer (NK) cells,
hypercytokinemia caused by these activated cells, and further
activation of these cells, that is, a malignant loop of excess cell
activation and cytokine production [2, 4, 5]. Cytokines in-
volved in HPS include interferon gamma (IFN-γ), macrophage
colony-stimulating factor (M-CSF), tumor necrosis fac-
tor alpha (TNF-α), and interleukin-6 (IL-6), IL-10, IL-
12, and IL-18 [4–10]. HPS mostly develops secondarily
to various infections, malignancies including hematological
neoplasm, and autoimmune diseases [2, 11].
Among these secondary HPS, the incidence of lymphoma-
associated hemophagocytic syndrome (LAHS) is relatively
high and its prognosis is poor compared with that of malignant
lymphoma without HPS [11–16]. Although early diagnosis
and appropriate chemotherapy for LAHS are important,
LAHS at an early stage does not always fulfill the diagnostic
criteria proposed by the International Histiocyte Society in
2004 (HLH-2004) [3]. In virus-associated hemophagocytic
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syndrome (VAHS), IFN-γ is a key cytokine that activates
macrophages and transforms them into hemophagocytic cells
[17–19]. The blood level of IFN-γ is elevated, and conse-
quently, this cytokine could be a diagnostic marker for VAHS
if rapid measurement is available. In LAHS, IFN-γ may also
play an important role; however, the exact key cytokine in
LAHS remains controversial [20–22]. Therefore, it is a press-
ing need to identify early markers for LAHS. For this purpose,
we have screened multiple chemokines/cytokines in the blood
of patients with LAHS.
Another problem in identifying these markers is the assay
system for cytokines. Sandwich enzyme-linked immunosor-
bent assay (ELISA) has been a gold standard technique for the
measurement of cytokines; however, ELISA has some disad-
vantages in terms of its employment as a routine laboratory
test in a hospital. ELISA is time-consuming and expensive,
and requires a large amount of serum. In recent years, a newly
developed technique, cytometric bead array (CBA) [23–27],
has been introduced in the field of clinical medicine [19,
28–32]. This assay system has resolved the majority of faults
of ELISA. CBA has enabled us to screen cytokine markers for
LAHS and rapidly obtain the result of multiple cytokine
concentrations in a small amount of specimen.
Design and methods
Patients
Fifteen adult lymphoma patients with LAHS and 18 without
LAHS were enrolled in the present study from May 2007 to
January 2010 in Kobe City Medical Center General Hospital.
The present study was a retrospective analysis of a single
institutional clinical study designated as “Cytokine Profile in
Lymphoma-Associated Hemophagocytic Syndrome,” which
had been approved by an institutional review board. Written
informed consent was obtained from all patients. The diagno-
sis of LAHS was made according to the criteria of Tsuda [1]
with some modifications: (1) high fever for more than a week;
(2) unexplained progressive cytopenia affecting at least two
cell lineages; (3) bone marrow showing mature histiocytes
comprising more than 3 % of nucleated cells with prominent
hemophagocytosis and/or hemophagocytosis in the liver,
spleen, or lymph node; and (4) definite diagnosis of malignant
lymphoma (modified by us). Of the LAHS patients in the
present study, nine had B-cell lymphomas (B-LAHS) and
six had T-cell/natural killer cell lymphomas (T/NK-LAHS).
As a control, 18 lymphoma patients without LAHS (non-
LAHS) were analyzed. Of these patients, 16 had B-cell lym-
phomas and two T/NK-cell lymphomas. The diagnosis of
malignant lymphoma was made according to the 2008
WHO Classification [33]. All patients diagnosed with LAHS
during the above mentioned period were enrolled in the
present study. Regarding non-LAHS patients, 18 patients
admitted during the same period were randomly selected for
the examination of the cytokine profile. Patient characteristics
and laboratory data are shown in Table 1. Other controls
included 20 healthy volunteers and nine sepsis patients with
hematologic malignancies (three patients with B-cell type
acute lymphoblastic leukemia, three myelodysplastic syn-
drome, one B-cell lymphoma, one T/NK-cell lymphoma,
and one multiple myeloma).
To determine the staging of lymphomas, a bone marrow
aspirate was evaluated for possible lymphoma cell invasion in
all lymphoma patients. Regarding the diagnosis of LAHS in
the present study, persistent high fever and progressive
cytopenia at presentation or on admission prompted us to
evaluate the marrow aspirate. As shown in Table 1, abnormal
lymphocytes and hemophagocytosis were concomitantly ob-
served. These abnormal lymphocytes were determined as of
lymphoid nature by flow cytometry. Because all these patients
except for those with intravascular large B-cell lymphoma
(IVL; Table 1) had superficial lymphadenopathy at presenta-
tion or on admission, a diagnosis of malignant lymphoma and
its subtype was established based on pathologic examination
of biopsied lymph nodes. Therefore, tentative diagnosis of
malignant lymphoma was made based on flow cytometry of
bone marrow cells before the final diagnosis by lymph node
biopsy in about 50% of LAHS patients. The final diagnosis of
IVL with hemophagocytosis (Table 1) was made based on the
presence of lymphoma cells in small vessels in the biopsy
specimen of the skin, lung, or bone marrow in addition to the
abnormal large lymphocytes in the bone marrow and their
phenotype by flow cytometry as described above.
Cytokine assay by CBA
The sera were collected at the time of hospitalization, acute
phase, remission after chemotherapy, and follow-up period
and kept frozen at −80 °C until analysis. G-CSF, IFN-γ, IL-
6, IL-8, IL-10, IP-10, MIG, MIP-1α, and TNF-α in the sera
were measured using CBA Flex Set kits (BD Biosciences, San
Jose, CA, USA). The minimum detection limits of these kits
were 1.6 pg/ml for G-CSF, 0.3 pg/ml for IFN-γ, 1.6 pg/ml for
IL-6, 1.2 pg/ml for IL-8, 0.1 pg/ml for IL-10, 0.5 pg/ml for IP-
10, 0.2 pg/ml for MIG, 0.2 pg/ml for MIP-1α, and 0.7 pg/ml
for TNF-α. The maximum detection limits of all kits were
2,500 pg/ml. When a cytokine concentration exceeded
2,500 pg/ml, diluted sera with an assay diluent were re-
assayed. The data were analyzed by FCAP Array Software
(BD Biosciences, San Jose, CA, USA).
Statistical analysis
Differences between two or three independent groups were
evaluated by Mann–Whitney U test and Kruskal–Wallis tests,
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followed by Dunn’s multiple-comparison test, respectively.
Analysis of multiple paired data was performed using
Friedman’s test, followed by Tukey’s multiple comparison
test. Rank correlation coefficient was determined using
Spearman’s rank correlation coefficient method. All calcula-
tions were carried out using the program JMP 8.0 (SAS
Institute Inc., Cary, NC, USA). P values of <0.05 were
considered to be significant.
Results
Patients with or without LAHS
As shown in Table 1, reflecting severe clinical features, all
indicated parameters (clinical stage, International Prognosis
Index, B symptom, white blood cell count, hemoglobin con-
centration, platelet count, lactate dehydrogenase (LDH), con-
centration of soluble IL-2 receptor (sIL-2R), and ferritin level)
except for subtype proportion of underlying lymphomas and
patient’s age were significantly different between LAHS and
non-LAHS groups. In addition, five of six non-LAHS patients
with B symptom had a fever as LAHS patients.
Comparison of serum cytokine concentrations
between LAHS, non-LAHS, and normal control groups
As shown in Fig. 1, serum concentrations of IP-10,MIG, IL-6,
IL-10, IFN-γ, and MIP-1α in the LAHS group were signifi-
cantly higher than those in the non-LAHS group. Of interest,
concentrations of IP-10 and MIG in the LAHS group were
extremely high, at more than 500 and 5,000 pg/ml,
respectively. Meanwhile, serum levels of IL-8, TNF-α, and
G-CSF did not significantly differ between the LAHS group
and the non-LAHS group (data not shown).
Comparison of serum cytokine concentrations between LAHS
and non-LAHS at similar clinical conditions
Because aggressive non-LAHS is clinically similar to LAHS,
we compared cytokine profile between patients with LAHS
and non-LAHS patients with advanced clinical stage (stage
IV), high international prognostic index (IPI), B symptom,
high LDH levels (more than two times of institutional upper
limit; 460 IU/L), and bone marrow involvement of the lym-
phoma. As shown in Table 2, serum concentrations of IP-10
and MIG in LAHS patients were significantly higher than
those in non-LAHS patients with these unfavorable parame-
ters, while concentrations of IFNγ in LAHS patients with high
LDH did not significantly differ from those in non-LAHS
patients with similar parameter, LDH. These results indicate
that high serum levels of IP-10 and MIG are characteristic of
lymphoma-associated hemophagocytosis.
Serum concentrations of IP-10 and MIG at the diagnosis
of LAHS and after chemotherapy
We then compared serum concentrations of IP-10, MIG, IL-6,
IL-10, IFN-γ, andMIP-1α at the diagnosis of LAHS and after
chemotherapy. The definition of the time when LAHS was
diagnosed was the day when hemophagocytosis was con-
firmed by bone marrow tap. In addition, all patients with
LAHS achieved complete or nearly complete remission after
chemotherapy. As shown in Fig. 2, serum concentrations of
Table 1 Characteristics of patients and their laboratory data
LAHS (n =15) Non-LAHS (n =18) P value
Underlying NHL B 9, T/NK 6 B 16, T/NK 2 NS
(DLBCL 5, IVL 4, AITL 1, ENKL 1, PTCL 4) (DLBCL 9, FL 5, MCL 2, PTCL 2)
Age 21–78 (61) 50–86 (65) NS
Stage Stage IV 15 Stage IV 11, stage I–III 7 <0.05
IPI High 14, high-intermediate 1 High 6, high-intermediate 4 <0.05
B symptom (+) 15 (+) 7, (−) 11 <0.001
BM invasion (+) 15 (+) 11 <0.05
WBC (×109/L) 0.4–8.2 (4.5) 2.1–11.2 (6.65) <0.005
Hb (g/dL) 7.5–10.4 (8.3) 7.7–17.0 (13.7) <0.001
PLT (×109/L) 8–142 (56) 84–499 (203) <0.001
LDH (IU/L) 210–4,021 (838) 109–3,985 (218) <0.002
sIL-2R (U/mL) 795–53,900 (13,870) 149–8,930 (1,385) <0.001
Ferritin (ng/mL) 579–36,555 (7,287) 80–3,038 (1,674) <0.001
Abbreviations: LAHS lymphoma-associated hemophagocytic syndrome,NHL non-Hodgkin’s lymphoma, IPI International Prognostic Index, BM bone
marrow,WBC white blood cell,Hb hemoglobin, PLT platelet, LDH lactate dehydrogenase, sIL-2R soluble interleukin-2 receptor,DLBCL diffuse large
B-cell lymphoma, IVL intravascular large B-cell lymphoma, AITL angioimmunoblastic T-cell lymphoma, ENKL extranodal NK/T-cell lymphoma,
PTCL peripheral T-cell lymphoma, FL follicular lymphoma, MCL mantle cell lymphoma, NS not significant
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IP-10, IL-6, IL-10, and MIP-1α, which were measured at the
time of admission, were not significantly different when com-
pared with those at the time of the diagnosis of LAHS,
indicating that these levels had already reached a high level
when the LAHS clinically manifested itself. Another analysis
was the comparison of cytokine concentrations at the time of
diagnosis with those at the time of remission after successful
chemotherapy. As shown in Fig. 2, concentrations of IP-10,
MIG, IL-10, and IFN-γwere significantly decreased compared
with those at the time of diagnosis of LAHS, indicating that
these cytokines are useful as markers of therapeutic outcomes.
Serum concentrations of IP-10 and MIG in LAHS patients at
the time of remission, however, were still significantly higher
(P <0.001 for both chemokines) than those in normal control
presumably due to heterogeneous remission conditions includ-
ing partial remission or post-remission chemotherapy. We
could repeatedly measure serum concentrations of these two
chemokines in three patients in complete remission after the
completion of chemotherapy and found all results to be within
normal levels.
Correlation between serum concentration of IP-10 and MIG
From the findings in the preceding paragraph, we selected IP-
10 and MIG as useful markers, and the sensitivity and spec-
ificity for the diagnosis of LAHS were 100 and 95 %, respec-
tively, when we set respective values (IP-10 500 pg/ml and
MIG 5,000 pg/ml) as the cut-off levels. In addition, we exam-
ined the correlation of these two chemokines in LAHS. The
concentrations of these two strongly correlated (R =0.732) in
LAHS and non-LAHS patients.
The relationship of cytokine concentrations with severity
of LAHS
We classified LAHS into two groups based on the severity of
HPS [11]. In this setting, we defined severe LAHS as when a































































Fig. 1 Serum cytokine profile in patients with LAHS, non-LAHS, and healthy controls. a IP-10, b MIG, c IL-6, d IL-10, e IFN-γ, f MIP-1α. NS not
significant
Table 2 Comparison of serum concentrations of IP-10, MIG, IFNγ, and










Stage IV n =15 n =11 <0.01 <0.05 <0.05 NS
IPI n =14 n =6 <0.01 <0.05 <0.05 NS
B symptom n =15 n =7 <0.01 <0.05 <0.05 NS
LDH (>460 IU/L) n =10 n =4 <0.05 <0.05 NS NS
BM invasion n =15 n =11 <0.01 <0.05 <0.05 NS
Concentrations of IP-10 and MIG in LAHS patients are significantly
higher than those in non-LAHS patients. Concentrations of IFNγ in
LAHS patients with high LDH did not significantly differ from those in
non-LAHS patients with similar parameter, LDH
LAHS lymphoma-associated hemophagocytic syndrome, IPI Internation-
al Prognostic Index, LDH lactate dehydrogenase, BM bone marrow, NS
not significant
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patients as havingmoderate/mild LAHS: platelet count: below
65×109/l, LDH: more than 750 IU/l, sIL-2R: more than
5,000 U/ml, and ferritin: more than 5,000 ng/ml. Figure 3
shows that only IP-10 and MIG could distinguish severe
LAHS from moderate/mild LAHS.
The difference of cytokine concentrations between B-LAHS
and T/NK-LAHS
Next, we analyzedwhether or not we can distinguish B-LAHS
from T/NK-LAHS using cytokine concentrations. Serum con-
centrations of IP-10, MIG, and IFN-γ were significantly
higher (P=0.005, 0.005, and 0.05, respectively) in T/NK-
LAHS than in B-LAHS, although the level of significance in
IFN-γ was low (P=0.05). Regarding IL-6, IL-10, and MIP-
1α, serum levels of these cytokines did not significantly differ
between the two groups.
IP-10 and MIG can distinguish LAHS from sepsis
Because of prominent inflammation in sepsis as in LAHS, we
analyzed whether we can distinguish LAHS from sepsis by
using blood levels of IP-10 and MIG. In this analysis, we
compared serum concentrations of IP-10 and MIG in LAHS
with those in nine patients with hematologic malignancies,
who developed sepsis. As shown in Fig. 4, serum concentra-
tions of IP-10 and MIG in sepsis patients were significantly
low compared with those in LAHS (P <0.001).
Discussion
In the present study, we identified IP-10 and MIG as being
useful markers for both the diagnosis of LAHS and therapeu-
tic outcomes for the following reasons: (1) serum concentra-
tions of these two chemokines at the time of LAHS diagnosis
were extremely high compared with those of other examined
cytokines; (2) the concentrations of these two chemokines
significantly decreased after successful chemotherapy; (3)
importantly, the scattering amplitude of values for these two
chemokines at three occasions was small (Fig. 2) compared
with that in other cytokines, including IFN-γ and IL-10,
which varied widely; and (4) the sensitivity and specificity
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Fig. 2 Changes in serum cytokine concentrations in 12 LAHS patients
on three occasions: three time points are on admission, at the time of
diagnosis, and during the remission of LAHS. The interval between the
time of admission and diagnosis is around 3 days. a IP-10, b MIG, c IL-
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Fig. 4 Comparison between serum concentrations of IP-10 andMIG in LAHS patients and those in patients with hematologicmalignancies complicated
with sepsis. a IP-10, b MIG, c IL-6, d IL-10, e IFN-γ, f MIP-1α. NS not significant
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when we set the cut-off values of IP-10 (500 pg/ml) and MIG
(5,000 pg/ml) at the LAHS diagnosis. Thus, these two
chemokines could be reliable markers for both diagnosis of
LAHS and its therapeutic outcomes. In the present study, we
included five patients with follicular lymphoma (FL) in non-
LAHS group that is one of controls to LAHS group. Although
FL is an indolent lymphoma, mean serum concentrations of
IP-10 (434.2 pg) and MIG (3,221.1 pg) in patients with FL
were comparable to those of IP-10 (417.0 pg) and MIG
(2,580.1) in patients with non-FL (n =13), respectively. There-
fore, it is unlikely that FL affected cytokine levels of IP-10 and
MIG in non-LAHS group because of its indolence.
IP-10 andMIG appeared also to be useful in distinguishing
both severe LAHS from moderate/mild LAHS and T/NK-
LAHS from B-LAHS. It was interesting that serum levels of
these two chemokines in T/NK-LAHS were higher than those
in B-LAHS, possibly reflecting higher cytokine production in
T/NK neoplasms than in B-cell tumors. Furthermore, these
two chemokines were also useful to distinguish LAHS from
sepsis in which blood levels of multiple inflammatory cyto-
kines are elevated [34–39]. From the findings described
above, both IP-10 and MIG are considered to be specific to
many aspects of LAHS.
The major producers of IP-10 and MIG are IFN-γ-
activated macrophages [40–42]. Among these activated mac-
rophages, resident macrophages more strongly express IP-10
than those derived from monocytes [43]. Neutrophils produce
these two chemokines [44], and dendritic cells and endothelial
cells also express IP-10 and MIG, respectively [45, 46]. Im-
portantly, IP-10 andMIG are chemo-attractants for activated T
cells, especially Th1 cells that produce IFN-γ [47–49]. There-
fore, IP-10 and MIG, which are produced by IFN-γ-activated
macrophages, attract Th1 cells through CXCR3 toward acti-
vated macrophages [48–50]. These mobilized Th1 cells pro-
duce IFN-γ and further activate macrophages to produce both
IP-10 and MIG. This loop may explain the high blood levels
of IP-10 and MIG during LAHS.
IFN-γ has been supposed to be one of the major mediators
of LAHS [20, 22]. However, its blood level was low during
LAHS in the present study. Furthermore, IFN-γ was not a
good marker for the diagnosis of LAHS. In the loop supposed
in the previous paragraph, IFN-γ production by Th1 cells
should be enhanced by persistent recruitment of Th1 cells
toward macrophages. Although the reason for this remains
to be elucidated, migrated Th1 cells might be able to activate
the loop even with a small amount of IFN-γ because Th1 cells
are mobilized close to macrophages. In other words, IFN-γ
may play a role as a trigger for the loop. Therefore, the present
study does not rule out the possible central role of IFN-γ in
LAHS. Rather, it is possible to assert that the initiator of
LAHS is not always a good marker for LAHS.
LAHSmay be initiated by cytokines derived from lympho-
ma cells, which activate macrophages in a direct or indirect
fashion. As a direct mediator, IFN-γ is the most likely cytokine.
As an indirect mediator, TNF-α, IL-1, or IL-2 is a possibility. In
this fashion, these cytokines activate T cells to produce IFN-γ.
However, the production of these cytokines by lymphoma cells
in LAHS has not been studied. In Hodgkin’s lymphoma, the
expression of IP-10, MIG, or IFN-γ was previously reported
[50]. Although this is an interesting finding, it is unclear wheth-
er these cytokines are directly produced by tumor cells.
In conclusion, we have shown specifically high blood
levels of IP-10 and MIG in LAHS as well as a strong corre-
lation between concentrations of these chemokines and clini-
cal status for the first time. We also demonstrated the useful-
ness of CBA in terms of rapid measurement of these
chemokines, which leads to early and proper diagnosis of
LAHS. Further studies are needed to elucidate the exact role
of IP-10 and MIG in the pathophysiology of LAHS.
Acknowledgments The authors would like to thank all the physicians
in Kobe CityMedical Center General Hospital for many useful comments
and help in general. We would also like to thank Kyoko Tanaka, Kobe
City Medical Center General Hospital, for technical assistance.
Funding This work was supported by Kasahara Foundation for the
Promotion of Cancer Research, KobeCityMedical Center General Hospital.
Disclosures The authors have no conflict of interest to disclose. The
authors also do not have a financial relationship with the Kasahara
Foundation for the Promotion of Cancer Research that financially sup-
ported the present study.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Tsuda H (1997) Hemophagocytic syndrome (HPS) in children and
adults. Int J Hematol 65:215–226
2. Imashuku S (1997) Differential diagnosis of hemophagocytic syn-
drome: underlying disorders and selection of the most effective
treatment. Int J Hematol 66:135–151
3. Henter JI, HorneA, AricóM, Egeler RM, FilipovichAH, Imashuku S,
Ladisch S, McClain K, Webb D, Winiarski J, Janka G (2007) HLH-
2004: diagnostic and therapeutic guidelines for hemophagocytic
lymphohistiocytosis. Pediatr Blood Canc 48:124–131
4. Henter JI, Elinder G, Söder O, Hansson M, Andersson B,
Andersson U (1991) Hypercytokinemia in familial hemophagocytic
lymphohistiocytosis. Blood 78:2918–2922
5. Fujiwara F, Hibi S, Imashuku S (1993) Hypercytokinemia in
hemophagocytic syndrome. Am J Pediatr Hematol Oncol 15:92–98
6. Akashi K, Hayashi S, Gondo H, Mizuno S, Harada M, Tamura K,
Yamasaki K, Uike N, Okamura T, Miyamoto T, Niho Y (1994)
Involvement of interferon-gamma and macrophage colony-
stimulating factor in pathogenesis of haemophagocytic
lymphohistiocytosis in adults. Br J Haematol 87:243–250
7. Osugi Y, Hara J, Tagawa S, Takai K, Hosoi G, Matsuda Y, Ohta H,
Fujisaki H, Kobayashi M, Sakata N, Kawa-Ha K, Okada S, Tawa A
Ann Hematol (2014) 93:393–401 399
(1997) Cytokine production regulating Th1 and Th2 cytokines in
hemophagocytic lymphohistiocytosis. Blood 89:4100–4103
8. Takada H, Nomura A, Ohga S, Hara T (2001) Interleukin-18 in
hemophagocytic lymphohistiocytosis. Leuk Lymphoma 42:21–28
9. Mazodier K, Marin V, Novick D, Farnarier C, Robitail S, Schleinitz
N, Veit V, Paul P, Rubinstein M, Dinarello CA, Harlé JR, Kaplanski
G (2005) Severe imbalance of IL-18/IL-18BP in patients with sec-
ondary hemophagocytic syndrome. Blood 106:3483–3489
10. Murohashi I, Yoshida K, Ihara N, Wakao D, Yagasaki F, Nakamura
Y, Kawai N, Matsuda A, Jinnai I, Bessho M (2006) Serum levels of
Th1/Th2 cytokines, angiogenic growth factors, and other prognostic
factors in young adult patients with hemophagocytic syndrome. Lab
Hematol 12:71–74
11. Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I,
Yamamoto K, Horiuchi H, Takada K, Ohshima K, Nakamura S,
Kinukawa N, Oshimi K, Kawa K (2007) Nationwide survey of
hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 86:58–65
12. Shimazaki C, Inaba T, Nakagawa M (2000) B-cell lymphoma-
associated hemophagocytic syndrome. Leuk Lymphoma 38:121–130
13. Takahashi N, Chubachi A, Kume M, Hatano Y, Komatsuda A,
Kawabata Y, Yanagiya N, Ichikawa Y, Miura AB, Miura I (2001)
A clinical analysis of 52 adult patients with hemophagocytic syn-
drome: the prognostic significance of the underlying diseases. Int J
Hematol 74:209–213
14. Go RS, Wester SM (2004) Immunophenotypic and molecular features,
clinical outcomes, treatments, and prognostic factors associated with
subcutaneous panniculitis-like T-cell lymphoma. Cancer 101:1404–1413
15. Han AR, Lee HR, Park BB, Hwang IG, Park S, Lee SC, Kim K, Lim
HY, Ko YH, Kim SH, Kim WS (2007) Lymphoma-associated
hemophagocytic syndrome: clinical features and treatment outcome.
Ann Hematol 86:493–498
16. Tong H, Ren Y, Liu H, Xiao F, Mai W, Meng H, Qian W, Huang J,
Mao L, Tong Y, Wang L, Qian J, Jin J (2008) Clinical characteristics
of T-cell lymphoma associated with hemophagocytic syndrome:
comparison of T-cell lymphoma with and without hemophagocytic
syndrome. Leuk Lymphoma 49:81–87
17. Ohga S, Matsuzaki A, Nishizaki M, Nagashima T, Kai T, Suda M,
Ueda K (1993) Inflammatory cytokines in virus-associated
hemophagocytic syndrome. Interferon-gamma as a sensitive indica-
tor of disease activity. Am J Pediatr Hematol Oncol 15:291–298
18. Imashuku S, Hibi S, Tabata Y, Sako M, Sekine Y, Hirayama K,
Sakazaki H, Maeda N, Kito H, Shichino H, Mugishima H (1998)
Biomarker and morphological characteristics of Epstein-Barr virus-
related hemophagocytic lymphohistiocytosis. Med Pediatr Oncol
31:131–137
19. Tang Y, Xu X, Song H, Yang S, Shi S, Wei J, Pan B, Zhao F, Liao C,
Luo C (2008) Early diagnostic and prognostic significance of a
specific Th1/Th2 cytokine pattern in children with haemophagocytic
syndrome. Br J Haematol 143:84–91
20. Miyahara M, Sano M, Shibata K, Matsuzaki M, Ibaraki K, Shimamoto
Y, Tokunaga O (2000) B-cell lymphoma-associated hemophagocytic
syndrome: clinicopathological characteristics. Ann Hematol 79:378–388
21. Murase T, Nakamura S, Kawauchi K,Matsuzaki H, Sakai C, Inaba T,
Nasu K, Tashiro K, Suchi T, Saito H (2000) An Asian variant of
intravascular large B-cell lymphoma: clinical, pathological and cyto-
genetic approaches to diffuse large B-cell lymphoma associated with
haemophagocytic syndrome. Br J Hematol 111:826–834
22. Ohno T, Ueda Y, Nagai K, Takahashi T, Konaka Y, Takamatsu T,
Suzuki T, SasadaM, Uchiyama T (2003) The serum cytokine profiles
of lymphoma-associated hemophagocytic syndrome: a comparative
analysis of B-cell and T-cell/Natural killer cell lymphomas. Int J
Hematol 77:286–294
23. Chen R, Lowe L, Wilson JD, Crowther E, Tzeggai K, Bishop JE,
Varro R (1999) Simultaneous quantification of six human cytokines
in a single sample using microparticle-based flow cytometric tech-
nology. Clin Chem 45:1693–1694
24. Cook EB, Stahl JL, Lowe L, Chen R, Morgan E, Wilson J, Varro R,
Chan A, Graziano FM, Barney NP (2001) Simultaneous measurement
of six cytokines in a single sample of human tears using microparticle-
based flow cytometry: allergics vs non-allergics. J Immunol Methods
254:109–118
25. Tárnok A, Hambsch J, Chen R, Varro R (2003) Cytometric bead
array to measure six cytokines in twenty-five microliters of serum.
Clin Chem 49:1000–1002
26. Morgan E, Varro R, Sepulveda H, Ember JA, Apgar J, Wilson J,
Lowe L, Chen R, Shivraj L, Agadir A, Campos R, Ernst D, Gaur A
(2004) Cytometric bead array: a multiplexed assay platform with
applications in various areas of biology. Clin Immunol 110:252–266
27. Varro R, Chen R, Sepulveda H, Apgar J (2007) Bead-based
multianalyte flow immunoassays: the cytometric bead array system.
Methods Mol Biol 378:125–152
28. Fujii N, Hiraki A, Aoe K, Murakami T, Ikeda K, Masuda K, Matsuo
K, Shinagawa K, Ishimaru F, Sugi K, Darzynkiewicz Z, Tanimoto M
(2006) Serum cytokine concentrations and acute graft-versus-host
disease after allogeneic peripheral blood stem cell transplantation:
concurrent measurement of ten cytokines and their respective ratios
using cytometric bead array. Int J Mol Med 17:881–885
29. Maier R, Weger M, Haller-Schober EM, EI-Shabrawi Y, Theisl A,
Barth A, Aigner R, Haas A (2006) Application of multiplex
cytometric bead array technology for the measurement of angiogenic
factors in the vitreous. Mol Vis 12:1143–1147
30. Falasca K, Vecchiet F, Ucciferri C, Vignale F, Conti P, Pizzigallo A,
Piatteli A, Vecchiet J (2008) Periodontitis and cytokine patterns in
HIV positive patients. Eur J Med Res 13:163–168
31. Ichiyama T, Shoji H, Takahashi Y, Matsushige T, Kajimoto M,
Inuzuka T, Furukawa S (2008) Cerebrospinal fluid levels of cyto-
kines in non-herpetic acute limbic encephalitis: comparison with
herpes simplex encephalitis. Cytokine 44:149–153
32. Tang Y, Liao C, Xu X, Song H, Shi S, Yang S, Zhao F, Xu W, Chen
X,Mao J, Zhang L, Pan B (2011) Evaluation of Th1/Th2 cytokines as
a rapid diagnostic tool for severe infection in paediatric haematology/
oncology patients by the use of cytometric bead array technology.
Clin Microbiol Infect 17:1666–1673
33. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H,
Thiele J, Vardiman JW (2008) WHO classification of tumours of
haematopoietic and lymphoid tissues, 4th edn. Lyon, IARC
34. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E
(1993) Serum cytokine levels in human septic shock. Relation to
multiple-system organ failure and mortality. Chest 103:565–575
35. Bossink AW, Paemen L, Jansen PM, Hack CE, Thijs LG, Van
Damme J (1995) Plasma levels of the chemokines monocyte chemo-
tactic proteins-1 and -2 are elevated in human sepsis. Blood 86:3841–
3847
36. Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa
A (1999) Change in the ratio of interleukin-6 to interleukin-10
predicts a poor outcome in patients with systemic inflammatory
response syndrome. Crit Care Med 27:1262–1264
37. Bozza FA, Gomes RN, Japiassú AM, Soares M, Castro-Faria-Neto
HC, Bozza PT, Bozza MT (2004) Macrophage migration inhibitory
factor levels correlate with fatal outocome in sepsis. Shock 22:309–313
38. Oberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze
A, Pribble JP, Moldawer LL (2005) Plasma cytokine measurements
augment prognostic scores as indicator of outcome in patients with
severe sepsis. Shock 23:488–493
39. Kellum JA, Kong L, FinkMP,Weissfeld LA, Yealy DM, PinskyMR,
Fine J, Krichevsky A, Delude RL, Angus DC (2007) Understanding
the inflammatory cytokine response in pneumonia and sepsis: results
of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.
Arch Intern Med 167:1655–1663
40. Luster AD, Unkeless JC, Ravetch JV (1985) Gamma-interferon
transcriptionally regulates an early-response gene containing homol-
ogy to platelet proteins. Nature 315:672–676
400 Ann Hematol (2014) 93:393–401
41. Ohmori Y, Hamilton TA (1990) A macrophage LPS-inducible early
gene encodes the murine homologue of IP-10. Biochem Biophys Res
Commun 168:1261–1267
42. Farber JM (1992) A collection of mRNA species that are inducible in
the RAW 264.7 mouse macrophage cell line by gamma interferon
and other agents. Mol Cell Biol 12:1535–1545
43. Narumi S, Hamilton TA (1991) Inducible expression of murine IP-10
mRNA varies with the state of macrophage inflammation activity. J
Immunol 146:3038–3044
44. Gasperini S,MarchiM, Calzetti F, Laudanna C,Vicentini L, OlsenH,
Murphy M, Liao F, Farber J, Cassatella MA (1999) Gene expression
and production of the monokine induced by IFN-gamma (MIG),
IFN-inducible T cell alpha chemoattractant (I-TAC) and IFN-
gamma-inducible protein-10 (IP-10) chemokines by human neutro-
phils. J Immunol 162:4928–4937
45. Yoneyama H, Narumi S, Zhang Y, Murai M, Baggiolini M,
Lanzavecchia A, Ichida T, Asakura H, Matsushima K (2002) Pivotal
role of dendritic cell-derived CXCL10 in the retention of T helper cell
1 lymphocytes in secondary lymph nodes. J ExpMed 195:1257–1266
46. Janatpour MJ, Hudak S, SatheM, Sedgwick JD, McEvoy LM (2001)
Tumor necrosis factor-dependent segmental control of MIG
expression by high endothelial venules in inflamed lymph nodes
regulates monocyte recruitment. J Exp Med 194:1375–1384
47. Bonecchi R, Bianchi G, Bordignon PP, D’Ambrosio D, Lang R,
Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia
F (1998) Differential expression of chemokine receptors and chemo-
tactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp
Med 187:129–134
48. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A (1998) Flexible
programs of chemokine receptor expression on human polarized T
helper 1 and 2 lymphocytes. J Exp Med 187:875–883
49. Meyer M, Hensbergen PJ, van der Raaij-Helmer EM, Brandacher G,
Margreiter R, Heufler C, Koch F, Narumi S, Werner ER, Colvin R,
Luster AD, Tensen CP, Werner- Felmayer G (2001) Cross
reactivity of three T cell attracting murine chemokines stimu-
lating the CXC chemokine receptor CXCR3 and their induc-
tion in cultured cells and during allograft rejection. Eur J
Immunol 31:2521–2527
50. Teruya-Feldstein J, Jaffe ES, Burd PR, Kingma DW, Setsuda JE,
Tosato G (1999) Differential chemokine expression in tissues in-
volved by Hodgkin’s disease: direct correlation of eotaxin expression
and tissue eosinophilia. Blood 93:2463–2470
Ann Hematol (2014) 93:393–401 401
